Drug Interactions between revakinagene taroretcel and Winco Foods Effervescent Antacid and Pain Relief

MONITOR: Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7. This interaction is sometimes exploited in the treatment of salicylate toxicity.

MANAGEMENT: Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.

ADJUST DOSING INTERVAL: Coadministration of revakinagene taroretcel ophthalmic with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of vitreous hemorrhage, which may result in temporary vision loss.

MANAGEMENT: The manufacturer of revakinagene taroretcel ophthalmic recommends temporarily interrupting antithrombotic medications before revakinagene taroretcel implantation. Patients should be advised to promptly report any signs of blurred vision, vision loss, floaters, or flashes of light. Clinicians should consult relevant literature, local and national treatment guidelines, and package labeling for further guidance.